Orizuru Therapeutics

ActiveOn the Japan Radar · not ranked

IPS cell therapies · Japan

Develops iPS cell-derived regenerative therapies, including pancreatic islet cells for diabetes and cardiomyocytes, and offers iPS platform services to pharmaceutical partners.

Biotech›iPS cell therapies orizuru-therapeutics.com

Last roundSeries B · Feb 2024

Why Orizuru Therapeutics is not ranked yet

How the Radar works →

The Radar lists every known eligible company, sorted by date of last round, with no AI judgement. Orizuru Therapeutics enters the ranking once its public data is sufficient for the AI to estimate it. Next Japan edition: 10 Jan 2027.

Funding history

Date	Round	Amount	Type	Investors
Feb 2024	Series B	USD 22M	—	Global Brain, Kyoto University Innovation Capital

Rounds as cited by Uback’s rankings. Equity, debt and grants are shown separately; only equity rounds count towards the valuation anchor.

Uback rankings

How the AI ranks →

Ranking	Tier	Rank	Edition	Next update
Japan · all sectors	Radar	—	Edition 0 · October 2026	10 Jan 2027

Independent analyses

By industry professionals & analysts

Industry professionals and financial analysts can publish their own analysis of Orizuru Therapeutics as a PDF. It must answer at least one of these four questions, and stick to them:

ValuationWhat is Orizuru Therapeutics worth?

Versus competitorsHow does it compare?

Who should acquire itStrategic buyers, and why

Who should it acquireAcquisition targets, and why

Publish an analysisName, role and LinkedIn shown · public sources only

Analyses are the opinion of their authors, not of Uback. They are checked before publication.

Invest

Back Orizuru Therapeutics whether or not it has agreed: your intention joins the pool on Orizuru Therapeutics, passed to the Fundraising Desk of its country once it reaches critical mass. Backing on Uback (pronounced “you back”) means declaring an Interest (free) or an Intention (coming soon). Backing does not mean that this company is raising funds or that a shareholder is selling shares, and it is not a commitment to invest. Any deal, through a funding round or a sale by an existing shareholder, is handled by a partner desk: the Fundraising Desk of the country for a round, the Secondary Sales Desk assigned to the company for a sale.

Back Orizuru Therapeutics Or back biotech in Japan

Pool on Orizuru TherapeuticsBelow threshold

BackersBelow threshold

Paid intention · valid for life · movable until you sign with a partner desk. If the company does not follow up, Uback invites its Backers to move their intentions to a competitor or a similar company. Investing in non-listed companies carries a risk of losing all the capital invested.

Do you run Orizuru Therapeutics?

Claim this profile to correct data, add your logo and description, or tell Uback about an upcoming round.

Claim this profile Report an upcoming round → Report an error →

Are you a shareholder?

Considering selling some of your shares? Tell Uback privately. Nothing is published without your consent, and never a price or a volume.

Tell Uback privately

What the AI reads

Read by the AI at the next edition.

Comparable companies in Japan

Full Japan ranking →

Sakana AI#1AI › foundation modelsUnicorn Preferred Networks#2AI › foundation models and AI chipsUnicorn CADDi#3Software › manufacturing AI and parts sourcingUnicorn Mujin#4Robotics › intelligent industrial robotsUnicorn

Last updated: Oct 2026Report an error

Uback is a content publisher and an aggregator of non-binding expressions of interest. It provides no investment advice, receives no mandate and takes part in no transaction. Rankings, ranges and brackets are editorial estimates produced by AI, purely indicative.